1 Prevalence and Characterization of Bacteria Present in the Nasopharynx of

2 Outpatients with and without SARS-CoV-2

- 3
- 4 James F. Shurko^{#1}, Chris A. Mares^{#2}, Robert B. Page², Kristina Lopez¹, Vivian Nguyen¹, Niti Vanee¹,
- 5 Pramod K. Mishra^{1*}
- 6
- ¹iGenomeDx, San Antonio, Texas, USA
- 8 ²Department of Life Sciences, Texas A&M University-San Antonio, San Antonio, Texas, USA
- 9
- [#]James F. Shurko and Chris A. Mares contributed equally to the preparation of this manuscript.
- 11 ^{*}Correspondence:
- 12 Pramod K. Mishra, iGenomeDx, 2040 Babcock Road, Suite 200, San Antonio, Texas, 78229,
- 13 pmishra@igenomedx.com.
- 14

- 16
- 17
- -
- 18
- 19
- 20
- 21
- 22

23

- 24
- 25
- 26

27 Abstract

28 COVID-19 has emerged as a highly contagious and debilitating disease caused by the SARS-CoV-2 virus 29 and has claimed the lives of over 6.8 million people worldwide. Bacterial co-infections are one of many 30 co-morbidities that have been suggested to impact the outcome of COVID-19 in patients. The primary 31 goal of this study was to assess the prevalence of bacterial co-infections and to describe any trends 32 observed during the height of the COVID-19 pandemic. To do this, we investigated SARS-CoV-2 and 33 bacterial co-infections from outpatient RT-PCR testing in Texas. The results indicate Staphylococcus 34 aureus, Streptococcus pneumoniae, Klebsiella pneumoniae, Moraxella catarrhalis, and Haemophilus 35 influenzae were the most frequently detected bacterial pathogens in both SARS-CoV-2 positive and 36 SARS-CoV-2 negative patients and that these bacterial pathogens were present in these two patient 37 populations at similar proportions. We also detected *Staphylococcus aureus* in a significantly larger 38 proportion of males relative to females and people under 65 years of age relative to those 65 and over. 39 Finally, we found that Hispanics were 75% more likely to be SARS-CoV-2 positive than non-Hispanics. 40 The results suggest that COVID-19 patients may benefit from rapid diagnostic tests for bacterial 41 pathogens and that this information could help delineate targeted antimicrobial therapy. 42 Introduction 43

Coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2
(SARS-CoV-2) and represents an important global health challenge. Approximately 6.8 million deaths
have been reported as due to COVID-19 globally with over one million occurring in the United States^{1,2}.
In the state of Texas alone, the CDC has reported a total of over 6.8 million cases and over 86 thousand
deaths since March of 2020. As of May 26th, 2022, the CDC reports an incidence of over 4.5 thousand
cases per day contributing to an average of 5 daily deaths³. While vaccines are available to the general
public in the United States, nearly 33.4% of the general population is not fully vaccinated (defined as

receiving two doses of either the Pfizer or Moderna vaccine or a single Dose of the Johnson and Johnson
vaccine) and in the State of Texas, approximately 34.4% of the population is not fully vaccinated^{4,5}.
These data, combined with the discovery of newly emerging strains, demonstrate that COVID-19 is a
continuing health concern⁶.

55 SARS-CoV-2 infections display a wide range of prognoses ranging from asymptomatic infection 56 to severe respiratory failure and death. More specifically, patients may experience fever, cough, fatigue, 57 dyspnea, diarrhea, loss of taste or smell, aches, conjunctivitis, pneumonia, acute respiratory distress syndrome (ARDS) and multi-organ failure^{7,8}. Currently, treatments for COVID-19 are limited and 58 controversial, with clinicians focusing largely on supportive care⁹⁻¹¹. In addition to comorbidities such as 59 60 hypertension and diabetes, bacterial co-infections have been shown to have a profound impact on the outcomes of patients infected with SARS-CoV-2¹²⁻¹⁵. Subsequently, empiric antimicrobial therapy has 61 62 been commonly administered to affected patients. Widespread antibiotic use remains controversial 63 however, due to increased healthcare costs, increased adverse drug reactions, and the evolution of 64 antimicrobial resistance. This study therefore aims to determine the effect of patient demographics 65 (age, sex, race and ethnicity) on the frequency of SARS-CoV-2 and bacterial infection, and to compare 66 the prevalence of common respiratory pathogens present within the nasopharynx of SARS-CoV-2 67 negative and SARS-CoV-2 positive patients. By elucidating the types of bacteria, frequency of bacterial 68 co-infection, and populations most likely to be infected, these data may aid in guiding the selection of 69 appropriate antimicrobials during infection as well as identify populations that are most likely to benefit 70 from concurrent respiratory pathogen testing or antibiotic use.

71

72 Results

Of the 4905 patients included in this data set 985 tested positive for SARS-CoV-2. Table 1 shows point
 estimates and 95% confidence intervals for the proportion of patients from various demographics (i.e.,

75	sex, age, ethnicity, and race) that were positive for SARS-CoV-2, S. aureus, and bacterial pathogens other
76	than <i>S. aureus</i> . Of the 12 tests conducted to compare positivity across these demographics, three were
77	statistically significant after correcting for multiple testing (Supplemental File 1). Despite fewer than half
78	(46.20%) of all patients self-reporting ethnicity, the positivity rate for SARS-CoV-2 was 75% higher in
79	Hispanics compared to non-Hispanics (Table 1). Further, the positivity rate for <i>S. aureus</i> was 23% higher
80	in males than females and 24% higher in patients under 65 years of age when compared to individuals
81	65 years of age or older (Table 1). Finally, there were no statistically significant differences in the
82	positivity rates of non-S. aureus bacteria detected across any of the demographic variables examined.
83	A total of eight bacterial pathogens were detected in this study including S. aureus (n = 1247), S.
84	pneumoniae (n = 184), M. catarrhalis (n = 157), K. pneumoniae (n = 129), H. influenzae (n = 91), M.
85	pneumoniae ($n = 3$), C. pneumoniae ($n = 4$) and Bordetella sp ($n = 4$). The estimated proportions and 95%
86	confidence intervals of SARS-CoV-2 positive and SARS-CoV-2 negative patients who tested positive for
87	each of these eight bacterial pathogens are shown in Figure 1. Three of these eight bacterial pathogens
88	(Bordetella sp., C. pneumoniae, and M. pneumoniae) were detected in fewer than five patients;
89	therefore, tests of equal proportions were not performed. Of the remaining five pathogens, tests
90	comparing positivity rates in SARS-CoV-2 negative and SARS-CoV-2 positive patients were not
91	statistically significant after correcting for multiple testing (Supplemental File 1).
92	Of the 4905 patients included in this study 1566 (31.9%) tested positive for at least one bacterial
93	pathogen and 471 (9.6%) patients tested positive for a pathogen other than <i>S. aureus</i> . Additionally, 213
94	(4.3%) patients tested positive for multiple bacterial pathogens and 85 (1.7%) patients tested positive
95	for multiple pathogens not counting S. <i>aureus</i> (Table 2). Contingency tables, odds ratios, 95% confidence
96	intervals, and <i>P</i> -values from Fisher's Exact Tests assessing the association between SARS-CoV-2 and
97	bacterial infection of any kind, bacterial infections other than S. aureus, polymicrobial infection including
98	S. aureus, and polymicrobial infection not including S. aureus are shown in Table 2. Upon correcting for

multiple testing, no significant associations were detected. However, the percentage of patients in
which multiple non-*S.aureus* bacteria were detected was more than twice as high in SARS-CoV-2
negative patients (1.9%) when compared to SARS-CoV-2 positive (0.91%) patients (Table 2).

102

103 Discussion

104 Among patients infected with SARS-CoV-2 globally, meta-analyses report a wide range (1-100%) of 105 antimicrobial prescribing rates. In the United States these rates generally range from 50% to 95% and are typically near 70%¹⁶⁻¹⁹. While some of these patients do suffer from bacterial co-infection or develop 106 107 secondary infections after admission, a disparity may exist between the rate of prescribing antibiotics 108 and the number of patients concurrently infected with SARS-CoV-2 and bacterial pathogens. As 109 antibiotics are prescribed, adverse drug reactions and antimicrobial resistance become concerns. With 110 studies identifying drug resistant organisms in SARS-CoV-2 patients treated with antibiotics, it has become imperative to determine the necessity of utilizing these agents^{20,21}. With studies identifying drug 111 112 resistant organisms in SARS-CoV-2 patients treated with antibiotics, it has become imperative to weigh 113 the risks and benefits of utilizing these agents. To address the necessity of prescribing antibiotics during 114 the current pandemic, we explored the propensity of SARS-CoV-2 infected patients to also experience 115 bacterial co-infection in the state of Texas. Further, we investigated whether patient demographics were 116 associated with the rate of SARS-CoV-2 or bacterial infection, as well as the types of bacteria and 117 number of polymicrobial infections present.

118 The rate of co-infection varies widely in the literature ranging from approximately 1 to 50 119 percent^{17,20,22-28}. Many factors may contribute to this variation including differences in geography, 120 setting (inpatient vs outpatient), time of collection (upon admission vs during hospital stay), site of 121 collection/sample type (sputum vs bronchiolar lavage vs nasopharyngeal swab etc.), and targeted 122 organisms (bacteria vs viruses or both). This study detected bacteria in 31.9 percent of patients including

123 32 percent among SARS-CoV-2 positive patients and 31 percent among SARS-CoV-2 negative patients. 124 While this bacterial co-infection rate may be higher than those estimated from many studies, it is typical 125 within the literature for studies utilizing nasopharyngeal swabs to observe higher rates of bacteria 126 compared to those drawing from other sources such as sputum. For example, a study conducted by 127 Calcogno et al., in which 75.9% of samples were collected via nasopharyngeal swabs, reported a similar rate (32.7 percent of patients overall in comparison to 31.9 percent in our study)²⁵. Additionally, 128 Calcogno et al.²⁵ identified *S. aureus* in 15.4 percent of patients while *S. aureus* was identified in 25.4% 129 130 percent of patients in our study. When combined with the notion that S. aureus colonizes the nares of a large portion of the general population, it's likely that the rate of infection, especially that by S. aureus 131 132 was inflated due to commensal bacteria. In addition to S. aureus our study identified H. influenza (1.8%), 133 K. pneumoniae (2.6%), S. pneumoniae (3.8%) and M. catarrhalis (3.2%) as the most common pathogens. 134 Similarly, in a meta-analysis by Musuuza et al., the most common respiratory pathogens detected in 135 patients co-infected with SARS-CoV-2 were K. pneumoniae (9.9%), S. pneumoniae (8.2%), S. aureus (7.7%). *H. influenzae* (6.6%), and *M. pneumoniae* (4.3%), and *M. catarrhalis* (1.7%)²⁹. Unlike in our 136 study however, Musuuza et al.²⁹ found that *M. pneumoniae* comprised 4.3% of the bacterial pathogens 137 138 identified, whereas our study only detected three instances of *M. pneumoniae*, all of which were SARS-139 CoV-2 negative patients.

While many factors potentially contribute to the similarities and differences between our results
and those of others, it is important to note that the types of bacterial infections observed may change
over time and/or differ considerably between outpatient and hospital settings. For example, *Acinetobacter, Pseudomonas,* and *Enterococcus* were more commonly identified after prolonged
hospital stays and multi-drug resistant organisms (MDROs) have been detected in hospitalized
patients^{20,29}. An additional limitation of comparing our results to the results of others is that the panels
of bacterial pathogens tested for often differs among studies. Thus, while it is expected for pathogens

147 associated with prolonged hospital stays to be less frequent in our outpatient population, use of the Fast 148 Tracking Diagnostics (FTD) panel limited our ability to fully assess their impact because it does not target 149 many of these organisms. Nevertheless, while the FTD panel may have limited the number of bacterial 150 species detected and therefore the overall infection rate, this limitation was partially addressed by 151 noting the presence of individual species. Additionally, separate analyses were conducted with and 152 without S. aureus. In doing so, infection rates of specific pathogens could be compared across groups or 153 between studies. Despite these limitations, this study is unique in that few studies have specifically 154 reviewed outpatient data and while several studies described the rate of co-infection in COVID-19 155 patients, few studied the difference in rate among SARS-CoV-2 positive and negative patients. However, 156 due to a lack of clinical follow up, culture, or genomic information, we were not able to describe the 157 effect of antimicrobial treatment on these patients. Overall, this study, and comparisons of our data 158 with data from other studies, show no evidence of an increased rate of bacterial infection among SARS-159 CoV-2 positive patients.

160 In addition to comparing the rate and types of bacterial infections in SARS-CoV-2 positive and 161 negative patients we sought to identify populations that may be at increased risk of either SARS-CoV-2 162 or bacterial infections. The data from this study confirm an increased rate of SARS-CoV-2 present in 163 Hispanics. This study was limited by its retrospective nature and self-reported demographics, of which 164 many patients declined to answer. Despite this limitation the proportion of Hispanics testing positive for SARS-CoV-2 is in line with data reported by the CDC³⁰. Notably 2639 patients did not disclose their 165 166 ethnicity and only 283 patients identified as non-Hispanic compared to 1983 patient who identified as 167 Hispanic. Consequently, the ethnicity of 53.8% of the patients is unknown and therefore volunteer bias 168 should be considered when interpreting these results. Despite this limitation, this study did uncover 169 that Hispanics were significantly more likely to be infected with SARS-CoV-2 when compared to non-170 Hispanics or when compared to those that did not self-report their ethnicity. Others have reported

171 similar observations, suggesting minorities have higher incidence and mortality rates due to COVID-19³¹⁻ 172 ³³. This study also found that *S. aureus* was more likely to be observed in men and adults below the age of 65, while other patient demographics did not appear to influence the presence of bacteria. 173 174 RT-PCR is currently the gold standard for detecting SARS-CoV-2, and in this study, this 175 technology was used concurrently with RT-PCR-based bacterial pathogen testing to ensure that no 176 systemic discrepancies existed in the sample collection and testing procedures. Using this approach, we 177 found a higher rate of detection of SARS-CoV-2 in Hispanics; however, no significant differences were 178 detected in the rate of bacterial infection between SARS-CoV-2 positive and SARS-CoV-2 negative 179 patients. Therefore, these data alone do not support an increase in the prescription of antimicrobials 180 due to the presence of SARS-CoV-2. We also detected S. aureus at higher rates in men and people under 181 65. However, S. aureus (the most commonly detected bacterium in our study) is observed in the nares of approximately 20%-30% of the population^{34,35}, suggesting that the presence of *S. aureus* in and of itself 182 183 is not necessarily indicative on infection—an issue we addressed by conducting separate analyses that 184 included and excluded *S. aureus*. Because this study was derived from outpatient settings at multiple 185 sites within the state of Texas, these data may not generalize to populations from other parts of the US. 186 However, by surveying outpatients, this study may be more applicable to the portion of the general 187 public that does not require hospitalization. Moreover, this study may provide utility in selecting 188 appropriate empiric therapies for patients who develop serious infections that require hospitalization. 189

190 Methods

191 Study design, sample collection & patient population

This study was a retrospective, multicenter analysis of outpatients concurrently tested for the presence
of SARS-CoV-2 as well as respiratory pathogens from April 2020 to April 2021. The patient population

was derived from within the state of Texas and patients were indicated for testing due to experiencing
symptoms such as cough, fever, etc.

196	Sample kits composed of requisition forms, nasopharyngeal swabs (Huachenyang iClean,
197	Shenzhen, China) and conical tubes (Stellar Scientific, Baltimore Maryland) containing storage buffer
198	were sent to outpatient facilities. Storage buffer was prepared according to CDC guidleines ³⁶ . Patient
199	demographics including sex, date of birth, ethnicity and race were included on the requisition forms and
200	self-reported by patients. Broad consent was provided by the patients at the time of testing. Prior to
201	analysis patient information was de-identified using the Safe Harbor Method ³⁷ . Specifically, date of
202	birth, provider, facility, insurance provider, and detailed geographic information such as zip codes etc.
203	were removed from the data set. This study was exempted from institutional review by the Institutional
204	Review Board at Texas A&M University-San Antonio (TAMUSA IRB #2022-016).

205

206 **RNA isolation and Pathogen Identification**

207 Bacteria were characterized by species, using RT-PCR. After nasal swab samples were obtained, RNA was 208 extracted using the Applied Biosystems MagMax Viral/Pathogen II kit (ThermoFisher, Waltham, MA) per 209 the manufacturer's instructions. After isolation, RNA was amplified and detected via RT-PCR using the 210 Applied Biosystems QuantStudio 7 flex and 12K flex systems (ThermoFisher, Waltham, MA). Primers, 211 probes and enzymes used to detect SARS-CoV-2 and bacteria were purchased from Integrated DNA 212 Technologies (Coralville, Iowa) and Fast Track Diagnostics (Sliema, Malta) respectively. Positive SARS-213 CoV-2 tests were defined as a cycle threshold (Ct) value of 40 or less for RNAse P, N1 and N2 collectively. 214 The Fast Track Diagnostics (FTD) respiratory kit contained probes for Bordetella spp, Chlamydia 215 pneumoniae, Haemophilus influenzae, Haemophilus influenzae type B, Klebsiella pneumoniae, Legionella 216 pneumophila, Moraxella catarrhalis, Mycoplasma pneumoniae, Salmonella spp, Staphylococcus aureus,

and Streptococcus pneumoniae. Bacterial infection was defined as a positive RT-PCR test in which the Ct
value was less than 35 for any of the respective probes.

219

220 Statistical analysis

221	This study is based on a subset of a larger data set generated from over 20 states and containing more
222	than 28,000 SARS-CoV-2 tests. These tests were conducted between the months of April 2020 and April
223	2021. All patients included in this study were administered SARS-CoV-2 and respiratory pathogen tests
224	concurrently. To ensure that analyses were based on a common suite of tests, only patients tested for
225	SARS-CoV-2 and all 11 respiratory pathogens described above were included. Additionally, to ensure
226	that all observations were independent, patients that were continually monitored or otherwise received
227	multiple tests were excluded. Given the differences in mitigation policy between states, and the fact
228	that Texas was the most heavily represented state in this data set, we focused on patients residing in
229	Texas for this study. After imposing these filters, the analyses we conducted were based on 4905
230	patients in total. These data are composed of patients from throughout the state of Texas; however,
231	1522 (31%) samples (i.e., patients) were collected in the McAllen-Edinburgh-Mission metropolitan
232	statistical area (MSA) and 2357 (48%) samples were collected from the San Antonio-New Braunfels MSA.
233	Thus, 79% of the samples that our analyses are based on come from these two MSAs. In addition, these
234	data include 1026 patients who did not disclose their city of residence, were from MSAs (e.g., Dallas-Fort
235	Worth) other than McAllen-Edinburgh-Mission and San Antonio-New Braunfels, or rural areas
236	throughout the state.
227	We used the (binem test) function in D to calculate point estimates and OEO(confidence intervals

We used the 'binom.test' function in R to calculate point estimates and 95% confidence intervals for the proportion of patients positive for SARS-CoV2, *S. aureus*, and bacterial pathogens other than *S. aureus*. This approach was applied across several demographic categories and was complemented by using R to test for equal proportions ('prop.test' function) among: (1) races, (2) ethnicities, (3) women vs. men, and (4) patients \geq 65 vs. patients < 65. We then adjusted the 12 resulting *P*-values (three pathogen categories x four demographic factors) for multiple testing using the False Discovery Rate (FDR = 0.05) correction described by Benjamini and Hochberg³⁸.

- 244 In addition to examining positivity rates across demographic factors, we also used 'binom.test'
- to compute point estimates and 95% confidence intervals of the proportion of SARS-CoV-2 positive and
- 246 SARS-CoV-2 negative patients who tested positive for each of the eight bacterial pathogens detected in
- our survey. We then used 'prop.test' to make comparisons between the bacterial positivity rates of
- 248 SARS-CoV-2-positive and SARS-CoV-2-negative patients for bacterial pathogens that had sufficient data
- to ensure that all expected cell counts were five or larger. The resulting five *P*-values were adjusted for
- 250 multiple testing by controlling the FDR at the 0.05 level³⁸.
- 251 Finally, we used the odds ratio (*OR*) to estimate the magnitude and direction of association
- between: (1) SARS-CoV-2 and detection of bacterial pathogens of any kind, (2) SARS-CoV-2 and
- detection of bacteria other than *S. aureus*, (3) SARS-CoV-2 and detection of more than one bacterium of
- any kind, and (4) SARS-CoV-2 and detection of more than one kind of bacteria, not including *S. aureus*.
- The null hypothesis that *OR* = 1.00 was assessed via Fisher's Exact Test and 95% confidence interval of
- 256 OR were computed using the 'fisher.test' function in R. The four resulting p-values were corrected for
- 257 multiple testing by controlling the FDR at the 0.05 level³⁸.
- 258

259 References

260	1	IHME. COVID-19 Projections United States of America, < <u>https://covid19.healthdata.org/united-</u>
261		<u>states-of-america?view=cumulative-deaths&tab=trend</u> > (
262	2	CDC. COVID-19 Integrated County View., < <u>https://covid.cdc.gov/covid-data-tracker/#county-</u>
263		<u>view</u> > (2022).
264	3	CDC. Compare Trends in COVID-19 Cases and Deaths in the US, < <u>https://covid.cdc.gov/covid-</u>
265		<u>data-tracker/#compare-trends_comptrends-deaths-daily-raw-lin</u> > (2022).
266	4	CDC. COVID-19 Vaccinations in the United States-Total Doses Administered,
267		<https: #vaccinations_vacc-total-admin-rate-total="" covid-data-tracker="" covid.cdc.gov=""> (2022).</https:>

268	5	CDC. COVID-19 Vaccinations in the United States Percent of People Receiving at Least One Dose,
269		< <u>https://covid.cdc.gov/covid-data-tracker/#vaccinations_vacc-people-onedose-percent-total.</u> >
270		(2022).
271	6	Dholariya, S. <i>et al.</i> Notable and Emerging Variants of SARS-CoV-2 Virus: A Quick Glance. <i>Indian J</i>
272		<i>Clin Biochem</i> 36 , 451-458, doi:10.1007/s12291-021-00991-0 (2021).
273	7	Pascarella, G. et al. COVID-19 diagnosis and management: a comprehensive review. J Intern Med
274		288 , 192-206, doi:10.1111/joim.13091 (2020).
275	8	CDC. Symptoms of COVID-19, < <u>https://www.cdc.gov/coronavirus/2019-ncov/symptoms-</u>
276		<u>testing/symptoms.html</u> > (2022).
277	9	Ohl, M. E. et al. Association of Remdesivir Treatment With Survival and Length of Hospital Stay
278		Among US Veterans Hospitalized With COVID-19. <i>JAMA Netw Open</i> 4 , e2114741,
279		doi:10.1001/jamanetworkopen.2021.14741 (2021).
280	10	Aleissa, M. M. et al. New Perspectives on Antimicrobial Agents: Remdesivir Treatment for
281		COVID-19. Antimicrob Agents Chemother 65 , doi:10.1128/AAC.01814-20 (2020).
282	11	NIH. Clinical Management,
283		< <u>https://www.covid19treatmentguidelines.nih.gov/management/clinical-management/</u> > (
284	12	Minh, L. H. N. et al. Clinical and laboratory factors associated with coronavirus disease 2019
285		(Covid-19): A systematic review and meta-analysis. <i>Rev Med Virol</i> 31 , e2288,
286		doi:10.1002/rmv.2288 (2021).
287	13	Mania, A. et al. Pneumonia, gastrointestinal symptoms, comorbidities, and coinfections as
288		factors related to a lengthier hospital stay in children with COVID-19-analysis of a paediatric part
289		of Polish register SARSTer. Infect Dis (Lond) 54 , 196-204, doi:10.1080/23744235.2021.1995628
290		(2022).
291	14	Shafran, N. et al. Secondary bacterial infection in COVID-19 patients is a stronger predictor for
292		death compared to influenza patients. <i>Sci Rep</i> 11 , 12703, doi:10.1038/s41598-021-92220-0
293		(2021).
294	15	De Santis, V. et al. Bacterial infections in critically ill patients with SARS-2-COVID-19 infection:
295		results of a prospective observational multicenter study. Infection 50, 139-148,
296		doi:10.1007/s15010-021-01661-2 (2022).
297	16	Langford, B. J. et al. Antibiotic prescribing in patients with COVID-19: rapid review and meta-
298		analysis. <i>Clin Microbiol Infect</i> 27 , 520-531, doi:10.1016/j.cmi.2020.12.018 (2021).
299	17	Rawson, T. M. et al. Bacterial and Fungal Coinfection in Individuals With Coronavirus: A Rapid
300		Review To Support COVID-19 Antimicrobial Prescribing. <i>Clin Infect Dis</i> 71 , 2459-2468,
301		doi:10.1093/cid/ciaa530 (2020).
302	18	Al-Hadidi, S. H. et al. The Spectrum of Antibiotic Prescribing During COVID-19 Pandemic: A
303		Systematic Literature Review. <i>Microb Drug Resist</i> 27, 1705-1725, doi:10.1089/mdr.2020.0619
304		(2021).
305	19	Calderon-Parra, J. et al. Inappropriate antibiotic use in the COVID-19 era: Factors associated with
306		inappropriate prescribing and secondary complications. Analysis of the registry SEMI-COVID.
307		<i>PLoS One</i> 16 , e0251340, doi:10.1371/journal.pone.0251340 (2021).
308	20	Khurana, S. et al. Profile of co-infections & secondary infections in COVID-19 patients at a
309		dedicated COVID-19 facility of a tertiary care Indian hospital: Implication on antimicrobial
310		resistance. Indian J Med Microbiol 39 , 147-153, doi:10.1016/j.ijmmb.2020.10.014 (2021).
311	21	Lai, C. C., Chen, S. Y., Ko, W. C. & Hsueh, P. R. Increased antimicrobial resistance during the
312		COVID-19 pandemic. Int J Antimicrob Agents 57, 106324, doi:10.1016/j.ijantimicag.2021.106324
313		(2021).

314	22	Son, H. J. et al. Risk factors for isolation of multi-drug resistant organisms in coronavirus disease
315		2019 pneumonia: A multicenter study. Am J Infect Control 49 , 1256-1261,
316		doi:10.1016/j.ajic.2021.06.005 (2021).
317	23	Cimolai, N. The Complexity of Co-Infections in the Era of COVID-19. SN Compr Clin Med 3, 1502-
318		1514, doi:10.1007/s42399-021-00913-4 (2021).
319	24	Alosaimi, B. et al. Influenza co-infection associated with severity and mortality in COVID-19
320		patients. <i>Virol J</i> 18 , 127, doi:10.1186/s12985-021-01594-0 (2021).
321	25	Calcagno, A. et al. Co-infection with other respiratory pathogens in COVID-19 patients. Clin
322		<i>Microbiol Infect</i> 27 , 297-298, doi:10.1016/j.cmi.2020.08.012 (2021).
323	26	Karaba, S. M. et al. Prevalence of Co-infection at the Time of Hospital Admission in COVID-19
324		Patients, A Multicenter Study. <i>Open Forum Infect Dis</i> 8 , ofaa578, doi:10.1093/ofid/ofaa578
325		(2021).
326	27	Lansbury, L., Lim, B., Baskaran, V. & Lim, W. S. Co-infections in people with COVID-19: a
327		systematic review and meta-analysis. <i>J Infect</i> 81 , 266-275, doi:10.1016/j.jinf.2020.05.046 (2020).
328	28	Sreenath, K. et al. Coinfections with Other Respiratory Pathogens among Patients with COVID-
329		19. <i>Microbiol Spectr</i> 9 , e0016321, doi:10.1128/Spectrum.00163-21 (2021).
330	29	Musuuza, J. S. et al. Prevalence and outcomes of co-infection and superinfection with SARS-CoV-
331		2 and other pathogens: A systematic review and meta-analysis. <i>PLoS One</i> 16 , e0251170,
332		doi:10.1371/journal.pone.0251170 (2021).
333	30	CDC. COVID-19 Weekly Cases and Deaths per 100,000 Population by Age, Race/Ethnicity, and
334		Sex, <https: #demographicsovertime="" covid-data-tracker="" covid.cdc.gov=""> (2022).</https:>
335	31	Karmakar, M., Lantz, P. M. & Tipirneni, R. Association of Social and Demographic Factors With
336		COVID-19 Incidence and Death Rates in the US. JAMA Netw Open 4, e2036462,
337		doi:10.1001/jamanetworkopen.2020.36462 (2021).
338	32	Zelner, J. et al. Racial Disparities in Coronavirus Disease 2019 (COVID-19) Mortality Are Driven by
339		Unequal Infection Risks. <i>Clin Infect Dis</i> 72 , e88-e95, doi:10.1093/cid/ciaa1723 (2021).
340	33	Khubchandani, J. & Macias, Y. COVID-19 vaccination hesitancy in Hispanics and African-
341		Americans: A review and recommendations for practice. Brain Behav Immun Health 15, 100277,
342		doi:10.1016/j.bbih.2021.100277 (2021).
343	34	Davis, K. A., Stewart, J. J., Crouch, H. K., Florez, C. E. & Hospenthal, D. R. Methicillin-resistant
344		Staphylococcus aureus (MRSA) nares colonization at hospital admission and its effect on
345		subsequent MRSA infection. Clin Infect Dis 39 , 776-782, doi:10.1086/422997 (2004).
346	35	Kuehnert, M. J. et al. Prevalence of Staphylococcus aureus nasal colonization in the United
347		States, 2001-2002. <i>J Infect Dis</i> 193 , 172-179, doi:10.1086/499632 (2006).
348	36	CDC. Preparation of Viral Transport Medium, < <u>https://www.cdc.gov/coronavirus/2019-</u>
349		ncov/downloads/Viral-Transport-Medium.pdf> (2021).
350	37	Kayaalp, M. Modes of De-identification. AMIA Annu Symp Proc 2017 , 1044-1050 (2017).
351	38	Benjamini, Y. a. H., Y. Controlling the false discovery rate: a practical and powerful approach to
352	-	multiple testing. <i>Journal of the Royal Statistics Society: Series B</i> 57 , 289-300 (1995).
353		
251		
354		

355 Author Contributions

Conceptualization, JFS, CAM, PKM, NV, and RBP. Methodology, JFS, RBP, PKM, KL, and VN. Analysis, JFS,
RBP, CAM, VN, KL, PKM. Writing, revising and editing, JFS, CAM, RBP, NV, and PKM.

358 Data Availability Statement

The data that support the findings of this study are available from the corresponding author, Dr. Pramod K. Mishra, upon reasonable request.

- Figure 1: Grouped bar plot comparing the proportions of SARS-CoV-2 positive patients (n = 985) and
- 365 SARS-CoV-2 negative patients (n = 3920) that tested positive for the various respiratory bacterial
- 366 pathogens detected during the study period. Error bars represent 95% confidence intervals for the
- 367 estimated proportions. Bs = Bordetella sp., Cp = C. penumoniae, Hi = H. influenzae, Kp = K. pneumoniae,
- 368 Mc = M. catarrhalis, Mp = M. pneumoniae, Sa = S. aureus, Sp = S. pneumoniae. Note that H. influenzae B,
- *L. pneumophila, and Salmonella sp.* were not detected in any patients and were therefore omitted.

386

Table 1. Proportion of patients who tested positive for SARS-CoV-2 or respiratory pathogens stratified

388 by demographic

Demograp	hic	Number of Patients	ients Proportion (95% Confidence interval)		
		n	SARS-CoV-2	S. aureus	Other ^a
Sex					<i>,</i>
Female		2837	0.1939 (0.1795-0.2089)	0.2330 (0.2175-0.2490)	0.0917 (0.08128-0.1029)
Male Undisclosed sex	,	2014	0.2105 (0.1929-0.2290)	0.2855 (0.2659-0.3058)	0.1033 (0.0903-0.1174)
Age		54	0.2037 (0.1063-0.3353)	0.2037 (0.1063-0.3353)	0.0556 (0.0116-0.1539)
≥ 65 years of ag	e	846	0.2163 (0.1890-0.2456)	0.2116 (0.1845-0.2407)	0.0780 (0.0609-0.0982)
< 65 years of ag		4037	0.1982 (0.1860-0.2108)	0.2631 (0.2495-0.2769)	0.0991 (0.0900-0.1087)
Undisclosed age		22	0.0909 (0.0112-0.2916)	0.2727 (0.1073-0.5022)	0.2273 (0.0782-0.4537)
Race					
African America	in	65	0.1846 (0.0992-0.3003)	0.2769 (0.1731-0.4019)	0.1077 (0.0444-0.2094)
Asian		36	0.1389 (0.0467-0.2950)	0.3056 (0.1635-0.4811)	0.0556 (0.0068-0.1866)
Native America	n	7	0.1429 (0.0036-0.5787)	0.2857 (0.0367-0.7096)	0.2857 (0.0367-0.7096)
Pacific Islander		1	0.0000 (0.0000-0.9750)	0.0000 (0.0000-0.9750)	0.0000 (0.0000-0.9750)
White		1892	0.2378 (0.2188-0.2577)	0.2775 (0.2574-0.2983)	0.0946 (0.0818-0.1087)
Undisclosed rac	e	2904	0.1780 (0.1643-0.1924)	0.2379 (0.2226-0.2539)	0.0968 (0.0863-0.1081)
Ethnicity		1983	0.2532 (0.2341-0.2729)	0.2552 (0.2361-0.2750)	0.0872 (0.7519-0.1005)
Hispanic Non-Hispanic		283	0.1449 (0.1060-0.1914)	0.3145 (0.2608-0.3721)	0.1060 (0.0727-0.1479)
Undisclosed eth	nicity	2639	0.1675 (0.1534-0.1823)	0.2471 (0.2307-0.2640)	0.1016 (0.0903-0.1137)
Total	intery	4905	012070 (012001 012020)		012020 (010000 012207)
389					
390	Proportio	ons and 95% confide	ence intervals (95% Cl) of pa	atients with SARS-CoV-2,	S. aureus and
391	(a) other	bacteria contained	in the respiratory testing pa	anel regardless of <i>S. aure</i>	eus presence.
392	Statistica	lly significant findin	gs are bolded.		
393					
394					
395					
396					
397					
398 399					
400					
400					

402

Table 2. Association between SARS-CoV-2 status and number of patients that tested positive for the various bacterial respiratory pathogens detected during the study period.

	COVIE) Status	<i>OR</i> (95% CI)	<i>p</i> -value	Adjusted p-value
One or more Bacteria of any kind	Positive	Negative			
Yes	309	1257			
No	676	2663			
Percentage	31	32	0.9684 (0.8302-1.1281)	0.7023	0.9306
One or more bacteria excluding S. aureus					
Yes	87	384			
No	898	3536			
Percentage	8.8	9.8	0.8921 (0.6907-1.1426)	0.3970	0.7940
Multiple bacteria of any kind					
Yes	42	171			
Νο	943	3749			
Percentage	4.3	4.4	0.9765 (0.6743-1.3871)	0.9306	0.9306
Multiple bacteria excluding S. aureus					
Yes	9	76			
Νο	976	3844			
Percentage	0.91	1.9	0.4665 (0.2047-0.9374)	0.02806	0.11224

405

406 Raw counts, odds ratios (OR), 95% confidence intervals (95% Cl), and p-values based on Fisher's Exact


407 Test of the null hypothesis that the true odds ratio is equal to one. Odds ratios describe how many times


408 more likely bacterial infection is given the presence of SARS-CoV-2.


409

410

411







Bs Cp Hi Kp Mc Mp Sa Sp **Respiratory Pathogen**